Impaired synaptic function and hyperexcitability of the pyramidal neurons in the prefrontal cortex of autism-associated Shank3 mutant dogs.
Feipeng Zhu, Qi Shi, Yong-Hui Jiang and 2 others
PMID 38297387WHAT IT FOUND
Dogs with an autism-associated Shank3 mutation had prefrontal neurons that fired more readily.
Glutamate synapses were weaker at low stimulation, and dendritic spines were fewer. This is basic animal brain work, not therapy evidence.
Key findings
01Prefrontal pyramidal neurons in Shank3 mutant dogs needed less current to fire action potentials (92.38 ± 12.07 pA) than wild-type controls (136.2 ± 17.13 pA).
02Low-intensity glutamate synaptic currents were smaller in mutant dogs (78.27 ± 9.34 pA) than in wild-type controls (104.6 ± 7.47 pA).
03Dendritic spines were fewer on prefrontal pyramidal neurons in mutant dogs (6.82 ± 0.71 per 10 μm) than in wild-type controls (14.71 ± 0.94).
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
Only six dogs were studied, three per genotype, and all were 3 to 4 months old. The dogs carried a specific heterozygous Shank3 exon 21 deletion, not the full range of human SHANK3 variants. The study measured neurons in brain slices after the dogs were killed, not live social behaviour or patient outcomes. The authors state it remains unclear how prefrontal neuron changes are linked to behavioural alterations. Single electron microscopy sections were used, and the authors note potential errors cannot be excluded.
Declared interests
The paper lists funding from STI2030-Major Projects and the National Natural Science Foundation of China; no author conflict-of-interest statement is supplied.
The easy way to misread this
Do not conclude that these dog neuron findings identify a treatment target for human autism or predict how patients will respond to therapy. The study measured brain slices from six young dogs, not people, and did not test any clinical intervention.